VHL Polyclonal Antibody - BT-AP15472

VHL Polyclonal Antibody

Sizes: 20μL, 50μL, 100μL

Catalogue Numbers: BT-AP15472-20, BT-AP15472-50, BT-AP15472-100

Citations, Manuals and MSDS Available upon request.

Background: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.

Research Areas: Metabolism; Cancer; Cell biology; Epigenetics and nuclear signaling

Target Protein: VHL

Applications: IHC-p, IF, ELISA

Reactivity: Human, Rat, Mouse

Clonality: Polyclonal

Host: Rabbit

Isotype: IgG

Full Product Name: Von Hippel-Lindau disease tumor suppressor

Immunogen: The antiserum was produced against synthesized peptide derived from human AMPK alpha around the phosphorylation site of Thr172. AA range:140-189

Storage: -20°C for 1 year

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Formulation: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Concentration: 1 mg/ml

UniProt Accession: Human: P40337; Mouse: P40338

Synonyms: Von Hippel-Lindau disease tumor suppressor;Protein G7;pVHL; Von Hippel-Lindau disease tumor suppressor; Protein G7; pVHL

GeneID: Human: 7428; Mouse: 22346

Research Use Only